Expert Advice • Next-Gen Incretin Science
Retatrutide vs Tirzepatide
Comparing current dual incretin therapy with the future of triple receptor agonism. Examine how the addition of glucagon activity fundamentally changes metabolic pathways.
Scientific Evolution
From Dual Incretins to the "Triple G" Era
When Tirzepatide arrived, it redefined clinical weight loss by adding GIP receptor agonism to standard GLP-1 stimulation. That dual pathway demonstrated that engaging complementary metabolic receptors produces outcomes well beyond single-hormone therapies.
Retatrutide represents the next evolutionary leap: a triple receptor agonist (often termed "tri-agonist" or "triple G"). It engages GIP, GLP-1, and glucagon receptors simultaneously within a single peptide molecule.
While Tirzepatide is currently licensed and widely prescribed in the UK under the brand Mounjaro®, Retatrutide remains in late-stage Phase 3 clinical evaluation (the TRIUMPH trial program), offering a clear look at the future of obesity medicine.
Comparative Matrix
Retatrutide vs Tirzepatide Comparison
Comparing molecular targets, clinical phase status, mechanism, and reported trial outcomes.
| Dimension | Tirzepatide | Retatrutide |
|---|---|---|
| Receptor Targets | Dual: GIP + GLP-1 | Triple: GIP + GLP-1 + Glucagon |
| Primary Developer | Eli Lilly & Company | Eli Lilly & Company |
| Regulatory Status (UK) | MHRA Approved (Mounjaro®) | Investigational (Phase 3 TRIUMPH trials) |
| Energy Expenditure Effect | Mainly appetite suppression & gastric delay | Appetite reduction + direct increase in metabolic rate |
| Trial Weight Reduction | Up to 22.5% at 72 weeks (SURMOUNT-1, 15 mg) | Up to 24.2% at 48 weeks (Phase 2, 12 mg) |
| Hepatic Fat Clearance | Significant liver fat reductions in trials | >80% reduction in liver fat at higher doses (Phase 2) |
| Cardiovascular Signals | Mild pulse increase; BP improvements | Dose-dependent heart rate increase peaking at week 24 |
The Decisive Difference
What Does Glucagon Agonism Add?
Thermogenesis & Energy
While GLP-1 and GIP primarily regulate intake (how much you consume), glucagon agonism directly increases energy output by stimulating metabolic rate and brown adipose tissue thermogenesis.
Hepatic Steatosis (Liver Fat)
Glucagon plays a fundamental role in liver lipid metabolism. Phase 2 Retatrutide data showed up to 86% of participants on higher doses resolved non-alcoholic fatty liver disease (MASLD).
Rate of Weight Loss
By attacking energy balance from both ends—reducing calorie intake and boosting calorie expenditure—Retatrutide achieved greater weight reduction in 48 weeks than earlier compounds reached in 68 to 72 weeks.
Clinical Observations
Tolerability & Cardiac Monitoring
How side effect profiles and physiological markers compare across clinical cohorts.
Gastrointestinal Symmetry
Both Tirzepatide and Retatrutide show similar GI event profiles. Mild to moderate nausea, diarrhoea, vomiting, and constipation remain the predominant complaints, occurring primarily during upward dose titration.
Phase 2 trials indicated that slower titration increments significantly attenuated the severity of GI symptoms with Retatrutide.
Heart Rate Differences
Glucagon receptors are expressed in sinoatrial nodal tissue. Retatrutide produced dose-dependent transient increases in resting pulse (peaking around 24 weeks before declining), which was observed more prominently than with Tirzepatide.
Ongoing Phase 3 trials continue to evaluate long-term cardiovascular safety profiles in diverse patient groups.
Frequently Asked Questions
Retatrutide vs Tirzepatide FAQs
Clear answers to the most common search questions comparing these two compounds.
Will Retatrutide replace Tirzepatide (Mounjaro)?
Not immediately. Tirzepatide has completed extensive Phase 3 trials and is widely licensed and established in the UK. Retatrutide is still in Phase 3 trials, with commercial availability anticipated in the coming years subject to regulatory approvals.
Is Retatrutide stronger than Tirzepatide?
In terms of trial endpoints, Retatrutide demonstrated higher mean weight reduction percentages (~24.2% at 48 weeks) than Tirzepatide reached over similar timeframes. This enhanced efficacy is largely attributed to the addition of glucagon receptor stimulation, which increases metabolic rate alongside appetite suppression.
Can you take Retatrutide and Tirzepatide together?
No. They both target GLP-1 and GIP receptors. Combining them would multiply receptor stimulation, dramatically elevating the incidence of severe gastrointestinal and cardiac side effects without providing therapeutic benefit.
How does liver fat response differ between the two?
Both compounds have shown remarkable efficacy in clearing liver fat. However, because glucagon receptors play an active direct role in hepatic fatty acid oxidation, Retatrutide demonstrated near-complete resolution of steatosis in more than 80% of patients evaluated in Phase 2 imaging studies.
Related Comparisons & Guides
Expand Your Clinical Reading
Semaglutide vs Tirzepatide
The premier clinical comparison of single vs dual incretins.
Retatrutide Profile
Full mechanism, ongoing trials, and peptide overview.
Tirzepatide Profile
Dual agonist profile, clinical trial data, and dosing.
Expert Advice Hub
Browse all clinical guides, comparisons, and explainers.
Purchasing & Options
Ready to Explore Compound Availability?
View current presentations, pack sizes, and verified options for both Retatrutide and Tirzepatide.